Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Merck Says Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) Of Keytruda Combined With Chemo Met Its Secondary Endpoint Of Overall Survival For Platinum-resistant Recurrent Ovarian Cancer In All Comers

Author: Benzinga Newsdesk | October 16, 2025 06:49am
  • KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovarian cancer to show a statistically significant improvement in OS versus placebo plus chemotherapy with or without bevacizumab for patients whose tumors express PD-L1 and in all comers
  • These data add to previous results for the primary endpoint of progression-free survival and key secondary endpoint of OS

Posted In: MRK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist